Nursing News

Memory improves for older adults using computerized brain-fitness program


Los Angeles, Cal., USA (June 25, 2013) - UCLA researchers have found that older adults who regularly used a brain-fitness program on a computer demonstrated significantly improved memory and language skills.


Rates of infection in intensive care units in England show impressive fall


NHS staff matched gains in controlling infection seen in the US


Leicester, UK (June 24, 2013) - Hospitals across England reduced the rate of serious bloodstream infections in intensive care units (ICUs) during a two-year programme, research has shown. More than 200 ICUs in England participated in the National Patient Safety Agency's Matching Michigan programme, which aimed to bring down infections linked to central venous catheters to the rate seen in a landmark programme in the US state of Michigan. Reducing the number of infections by more than 60%, the English ICUs were able to equal the low rates seen in the US.


Vitamin D reduces blood pressure and relieves depression in women with diabetes


MAYWOOD, Il., USA (June 24, 2013) - In women who have type 2 diabetes and show signs of depression, vitamin D supplements significantly lowered blood pressure and improved their moods, according to a pilot study at Loyola University Chicago Niehoff School of Nursing. Vitamin D even helped the women lose a few pounds. The study was presented at the American Diabetes Association 73rd Scientific Sessions in Chicago.


FDA approves Vibativ for hospitalized patients with bacterial pneumonia


Silver Spring, MD, USA (June 21, 2013) - The U.S. Food and Drug Administration today expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Vibativ should be used for the treatment of HABP/VABP only when alternative treatments are not suitable.


Studies demonstrate the strategy to kill melanoma by sensitizing resistant cells

Diabetes drug points the way to overcoming drug resistance in melanoma


Philadelphia, PA, USA (June 13, 2013) - Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.


American Society of Clinical Oncology

New cancer drug shows promise for treating advanced melanoma


Los Angeles, CA, USA (June 2, 2013) - Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.


Doctors prescribe more analgesics to women than to men just for being female


Madrid, Spain (May 21, 2013) - Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is influenced by socioeconomic inequality between genders in the Autonomous Community in which the patient resides.


FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding


Silver Spring, MD (April 29, 2013) - The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States.


Seven new medicines recommended for approval

EMA-Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013


London (April 26, 2013) - This page provides an overview of the opinions adopted at the April 2013 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes. 

  • The Committee recommended the approval of the first combined tissue-engineered medicine to be authorised across the European Union (EU). MACI (matrix-induced autologous chondrocyte implantation) is an advanced-therapy medicinal product (ATMP) intended for the repair of cartilage defects.
  • The Committee also gave a positive recommendation for the approval of Nuedexta, the first medicine for pseudobulbar effect approved in the EU.
  • Four medicines to treat cancer received a positive opinion by the Committee:  Erivedge, for the treatment of advanced basal cell carcinoma; Xtandi, for the treatment of prostate cancer and the two generic medicines Capecitabine Sun and Imatinib Accord.
  • The CHMP also recommended that Spedra should be granted a marketing authorisation for the treatment of erectile dysfunction.

Supplement helped control blood-sugar levels in obese youths

Vitamin D May Lower Diabetes Risk in Obese Children and Adolescents, MU Study Finds


Columbia, Mo., USA (March 26, 2013) – Childhood and adolescent obesity rates in the United States have increased dramatically in the past three decades. Being obese puts individuals at greater risk for developing Type 2 diabetes, a disease in which individuals have too much sugar in their blood. Now, University of Missouri researchers found vitamin D supplements can help obese children and teens control their blood-sugar levels, which may help them stave off the disease.


European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type 2 diabetes


London (March 26, 2013) - The European Medicines Agency is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis (inflammation of the pancreas) and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with so-called GLP-1-based therapies (glucagon-like peptide 1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors).


Large-scale study finds vitamin supports lung function as well as bone health

Vitamin D benefits breathing in tuberculosis patients


Chevy Chase, MD, USA (March 26, 2013) - Maintaining adequate levels of vitamin D can help people breathe better and may even protect against tuberculosis (TB), according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

The study of more than 10,000 Korean adults found that lung function improved when people had absorbed more vitamin D into their bodies. Vitamin D is absorbed primarily through sunlight, with a healthy diet as a secondary source.



Temporary Tattoos May Put You at Risk


Silver Spring, MD, USA (March 25, 2013) - Spring break is on the way, or maybe summer vacation. Time to pack your swim suit, hit the beach, and perhaps indulge in a little harmless fun. What about getting a temporary tattoo to mark the occasion? Who could it hurt to get a temporary tattoo?

It could hurt you, if you actually get one. Temporary tattoos typically last from three days to several weeks, depending on the product used for coloring and the condition of the skin. Unlike permanent tattoos, which are injected into the skin, temporary tattoos marketed as "henna" are applied to the skin's surface.



Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2013


London (March 23, 2013) - This page provides an overview of the opinions adopted at the March 2013 meeting of the CHMP and other important outcomes. In the table below, readers can view the main opinions adopted at the meeting, as well as information on referral procedures.

The Agency publishes a new page following the CHMP meeting each month.

Report by World Health Organization, UCLA School of Nursing shows nursing, midwifery can have major impact on lifestyles changes, health outcomes

Nurses can play key role in reducing deaths from world's most common diseases


Los Angeles, Cal., USA (March 19, 2013) - Nurses and midwives can play a critical role in lessening people's risk of cardiovascular diseases, cancers, chronic respiratory disease and diabetes, according to a groundbreaking new report issued by the World Health Organization and co-authored by a UCLA nursing professor.


Living in a sunny climate does not improve vitamin D levels in hip fracture patients


CHICAGO, Ill., USA (March 19, 2013) – While it is well known that a majority of hip fracture patients of all ages and both sexes have insufficient or deficient levels of vitamin D, a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) looks at whether or not living in a warm, sunny climate improves patient vitamin D levels.


FDA approves Osphena for postmenopausal women experiencing pain during sex


Silver Spring, MD, USA (February 26, 2013) - The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.


FDA alerts health care providers of recall of anemia drug Omontys


Silver Spring, MD, USA (February 24, 2013) - The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill. The recall is due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients.


Preventing chronic pain with stress management


Montreal, Canada (February 24, 2013) - For chronic pain sufferers, such as people who develop back pain after a car accident, avoiding the harmful effects of stress may be key to managing their condition. This is particularly important for people with a smaller-than-average hippocampus, as these individuals seem to be particularly vulnerable to stress. These are the findings of a study by Dr. Pierre Rainville, PhD in Neuropsychology, Researcher at the Research Centre of the Institut universitaire de gériatrie de Montréal (IUGM) and Professor in the Faculty of Dentistry at Université de Montréal, along with Étienne Vachon-Presseau, a PhD student in Neuropsychology. The study appeared in Brain, a journal published by Oxford University Press.


FDA approves new treatment for late-stage breast cancer


Silver Spring, MD, USA (February 22, 2013) - The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

HER2 is a protein involved in normal cell growth. It is found in increased amounts on some types of cancer cells (HER2-positive), including some breast cancers. In these HER2-positive breast cancers, the increased amount of the HER2 protein contributes to cancer cell growth and survival.


CDC: Drug overdose deaths increase for 11th consecutive year

Opioids drive continued increase in drug overdose deaths


Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th consecutive year in 2010, according to an analysis from the Centers for Disease Control and Prevention. The findings are published today in a research letter, “Pharmaceutical Overdose Deaths, United States, 2010,” in the Journal of the American Medical Association (JAMA).


Agency requires post-approval safety studies to assess rare events

FDA approves new silicone gel-filled breast implant


Silver Spring, MD, USA (February 20, 2013) - The U.S. Food and Drug Administration today approved the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. Natrelle 410 implants are manufactured by Allergan, Inc.


Delirium can lead to short- and long-term confusion and memory problems

Simple measures to promote sleep can reduce delirium in intensive care patients


Baltimore, Maryland, USA (February 20, 2013) - A hospital is not the best place to get a good night's sleep, especially in a noisy intensive care unit. It's a cause for concern because studies have shown that a lack of sleep can cause patients to experience delirium—an altered mental state that may delay their recovery and lead to short and long-term confusion and memory problems.


Can Insurers Save Money by Providing Free Diabetes-Related Medications and Supplies?


New Rochelle, NY (February 20, 2013) Reducing financial barriers to medication access—a strategy known as value-based insurance design (VBID)—can improve medication adherence and management of chronic diseases such as diabetes. The economic and patient-perceived benefits of eliminating co-payments for diabetes-related medications and supplies are described in a trend-setting study published in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Population Health Management website.


Cost-effectiveness of medicare drug plans in schizophrenia and bipolar disorder


Pittsburgh, Pennsylvania (February 19, 2013) – A new study published online today in the American Journal of Managed Care found that in Medicare Part D, generic drug coverage was cost-saving compared to no coverage in bipolar disorder and schizophrenia, while also improving health outcomes. Researchers from the University of Pittsburgh School of Medicine, the Pitt Graduate School of Public Health, and Western Psychiatric Institute and Clinic of UPMC note that policymakers and insurers should consider generic-only coverage, rather than no gap coverage, to both conserve health care resources and improve health.



Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®


Bagsværd, Denmark (February 10, 2013) – Novo Nordisk today announced that on 8 February 2013 it received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the New Drug Applications for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart). A Complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form.

In the letter, the FDA requests additional cardiovascular data from a dedicated cardiovascular outcomes trial before the review of the New Drug Applications can be completed. Novo Nordisk is evaluating the content of the Complete Response Letter and will work closely with the FDA to provide the requested data. Novo Nordisk does not expect to be able to provide the requested data during 2013.


Multiple myeloma

FDA approves Pomalyst for advanced multiple myeloma


Silver Spring, MD, USA (February 8, 2013) - The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow. According to the National Cancer Institute, approximately 21,700 Americans are diagnosed with multiple myeloma and 10,710 die yearly from the disease.


Breast Milk Reduces Risk of Sepsis and Intensive Care Costs in Very-Low-Birth-Weight Infants


Chicago, Ill., USA (February 6, 2013) — Feeding human breast milk to very-low-birth-weight infants greatly reduces risk for sepsis and significantly lowers associated neonatal intensive care unit (NICU) costs, according to a study by Rush University Medical Center researchers.


Low vitamin D levels may increase risk of Type 1 diabetes


Boston, MA, USA (February 4, 2013) – Having adequate levels of vitamin D during young adulthood may reduce the risk of adult-onset type 1 diabetes by as much as 50%, according to researchers at Harvard School of Public Health (HSPH). The findings, if confirmed in future studies, could lead to a role for vitamin D supplementation in preventing this serious autoimmune disease in adults. The study was published online February 3, 2013 and will appear in the March 1 print edition of the American Journal of Epidemiology.



Patients can emit small, influenza-containing particles into the air during routine care


Winston-Salem, NC, USA (January 31, 2013) - A new study suggests that patients with influenza can emit small virus-containing particles into the surrounding air during routine patient care, potentially exposing health care providers to influenza. Published in The Journal of Infectious Diseases, the findings raise the possibility that current influenza infection control recommendations may not always be adequate to protect providers from influenza during routine patient care in hospitals.


Eating deep-fried food is associated with an increased risk of prostate cancer


  • Frequent, regular consumption has strongest effect and is linked to more aggressive disease


Seattle, WA, USA (January 28, 2013) – Regular consumption of deep-fried foods such as French fries, fried chicken and doughnuts is associated with an increased risk of prostate cancer, and the effect appears to be slightly stronger with regard to more aggressive forms of the disease, according to a study by investigators at Fred Hutchinson Cancer Research Center.


FDA approves Gleevec for children with acute lymphoblastic leukemia


Silver Spring, MD, USA (January 25, 2013) - The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually, and progresses quickly if untreated. Children with Ph+ ALL have a genetic abnormality that causes proteins called tyrosine kinases to stimulate the bone marrow to make too many immature white blood cells. This leaves less room for healthy white blood cells needed to fight infection.


FDA approves three new drug treatments for type 2 diabetes


Silver Spring, MD,USA (January 25, 2013) - The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.


Novartis Europharm Ltd withdraws its marketing authorisation application for Ruvise (imatinib mesilate)


London, UK (January 24, 2013) - The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ruvise (imatinib mesilate), 100 and 400 mg film-coated tablets. It was intended to be used for adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH).


Vaccinating children against rotavirus may indirectly protect adults too, study finds


Arlington, VA, USA (January 24, 2013) - Pediatric rotavirus vaccination also indirectly protects unvaccinated adults from the highly contagious cause of severe diarrhea and vomiting, suggests a new study published in Clinical Infectious Diseases and available online. The findings suggest pediatric immunization against the virus may be more cost effective than previously thought, given rotavirus-related health care costs among adults.


FDA approves Exjade to remove excess iron in patients with genetic blood disorder


First imaging companion diagnostic to detect liver iron concentration also cleared


Silver Spring, MD, USA (January 23, 2013) - The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

NTDT is a milder form of thalassemia that does not require individuals to get frequent red blood cell transfusions. However, over time, some patients with NTDT are still at risk for iron overload that can lead to damage to vital organs.


New NICE guidance on psychosis and schizophrenia in children and young people


London, UK (January 23, 2013) - New NICE guidance stresses that signs of psychosis and schizophrenia in children and young people need to be identified early to help ensure they receive the treatment and care they need to live with the condition. NICE, the healthcare guidance body, has today (23 January) published a new clinical guideline on the recognition and management of psychosis and schizophrenia in children and young people up to the age of 18.


Hyperbaric treatment has significantly resuscitated activity in damaged brains, TAU researchers find

Oxygen Chamber Can Boost Brain Repair


Tel Aviv, Israel (January 23, 2013) - Stroke, traumatic injury, and metabolic disorder are major causes of brain damage and permanent disabilities, including motor dysfunction, psychological disorders, memory loss, and more. Current therapy and rehab programs aim to help patients heal, but they often have limited success.


Mayo Clinic:

Proper techniques for newborn bathing and skin care basics


ROCHESTER, Minn. , USA (January 22, 2013) - Bathing a tiny newborn can be an exciting experience for parents, but it can also be intimidating. Newborns are small and vulnerable, slippery when wet, and the products marketed for their delicate skin can leave parents with abundant choices. As newborns are welcomed into the world, their skin needs to adapt to the new environmental changes around them. It's important for parents to understand proper bathing techniques and the appropriate skin care needed for their little one.


Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013


London, UK (January 18, 2013) - This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. In the table below, readers can view the main opinions adopted at the meeting, as well as information on referral procedures. The new public-health communication document on Agency’s recommendation to suspend Tredaptive, Pelzont and Trevaclyn combines the press release and question-and-answer document previously published following CHMP meetings. The Agency publishes a new page following the CHMP meeting each month.

FDA approves Botox to treat overactive bladder


Silver Spring, MD, USA (January 18, 2013) - The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

Overactive bladder is a condition in which the bladder squeezes too often or squeezes without warning. Symptoms include leaking urine (urinary incontinence), feeling the sudden and urgent need to urinate, and frequent urination.